The Myogenesis Program Drives Clonal Selection and Drug Resistance in Rhabdomyosarcoma
Preprint
Abstract
Rhabdomyosarcoma (RMS) is a pediatric cancer with features of skeletal muscle; patients with unresectable or metastatic RMS fare poorly due to high rates of disease recurrence. Here, we use single cell and single nucleus RNA-sequencing to show that RMS tumors recapitulate the spectrum of embryonal myogenesis. Using matched patient samples from a clinical trial and orthotopic patient-derived xenografts (O-PDXs), we show chemotherapy eliminates the most proliferative component with features of myoblasts; after treatment, the quiescent immature population with features of paraxial mesoderm expands to reconstitute the developmental hierarchy of the original tumor. We discovered that this paraxial mesoderm population is dependent on EGFR signaling and is sensitive to EGFR inhibitors. Taken together, this data serves as a proof-of-concept that targeting each developmental state in RMS is an effective strategy for improving outcomes by preventing disease recurrence.Keywords
All Related Versions
- Published version: Developmental Cell, 57 (10), 1226.
This publication has 38 references indexed in Scilit:
- The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communitiesDevelopmental Biology, 2016
- Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.Cancer Discovery, 2014
- Gene Regulatory Networks and Transcriptional Mechanisms that Control MyogenesisDevelopmental Cell, 2014
- Targeting Oxidative Stress in Embryonal RhabdomyosarcomaCancer Cell, 2013
- EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA TechnologyClinical Cancer Research, 2011
- Immunohistochemical detection of EGFR, fibrillin‐2, P‐cadherin and AP2β as biomarkers for rhabdomyosarcoma diagnosticsHistopathology, 2009
- Subtype and Prognostic Classification of Rhabdomyosarcoma by ImmunohistochemistryJournal of Clinical Oncology, 2006
- Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcomaLaboratory Investigation, 2006
- Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas: Figure 1Journal of Clinical Pathology, 2003
- Comparison of Various Envelope Proteins for Their Ability to Pseudotype Lentiviral Vectors and Transduce Primitive Hematopoietic Cells from Human BloodMolecular Therapy, 2002